ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1 - Pharmaceutical Technology

At ADA 2026, findings from the Phase III TRIUMPH-1 trial were presented, assessing Eli Lilly's retatrutide in adults with obesity or overweight and at least one weight-related comorbidity. Key opinion leaders interviewed by GlobalData have anticipated the TRIUMPH-1 readout with considerable interest. Retatrutide is currently in Phase III investigation globally across obesity, overweight, T2D, cardiovascular disease, and other diseases. Credit: Cynthia A Jackson via Shutterstock.com. On 6 June, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, findings from the Phase III TRIUMPH-1 trial (NCT05929066) were presented, assessing Eli Lilly’s retatrutide in adults with…

GlobalData Healthcare · 2026-06-18

At ADA 2026, findings from the Phase III TRIUMPH-1 trial were presented, assessing Eli Lilly's retatrutide in adults with obesity or overweight and at least one weight-related comorbidity.

Source: Pharmaceutical Technology